Press Release

Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity

Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy in myasthenia gravis (MG) remains on track for mid-2024 Positive 12-month follow-up data from Phase 2a study in MG reported today; durable depletion of autoantibodies and clinically meaningful improvements in MG severity scores observed approximately 10 months after last …

Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity Read More »

Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis

Durable depletion of autoantibodies and clinically meaningful improvements in myasthenia gravis (MG) severity scores observed after one-year follow-up period without need for lymphodepleting chemotherapy Descartes-08 observed to be well tolerated following administration in outpatient setting Publication is in peer review and available on the preprint server, medRxiv Topline data from Phase 2b placebo-controlled study continues …

Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis Read More »

Selecta Biosciences Announces Merger with Cartesian Therapeutics

– Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian’s wholly owned pipeline includes a Phase 2 lead asset, Descartes-08, for which deep and durable responses have been observed in patients with myasthenia gravis (MG) – – Multiple near-term catalysts, including data from …

Selecta Biosciences Announces Merger with Cartesian Therapeutics Read More »

Cartesian Therapeutics Announces Landmark Study in The Lancet Neurology of First Successful Clinical Trial of RNA Cell Therapy in Autoimmunity

Modifying patients’ T-cells with mRNA to express a chimeric antigen receptor (rCAR-T therapy), a novel approach to treat myasthenia gravis and other autoimmune diseases. Gaithersburg, MD—June 22, 2023 – Cartesian Therapeutics, a clinical-stage biotechnology company pioneering cell therapies for autoimmune diseases, announced today the publication of a landmark paper in The Lancet Neurology. The study describes …

Cartesian Therapeutics Announces Landmark Study in The Lancet Neurology of First Successful Clinical Trial of RNA Cell Therapy in Autoimmunity Read More »

Cartesian Therapeutics Announces Appointment of Three World-Renowned Scientists and Engineers as Charter Members of Company’s Scientific Advisory Board

Gaithersburg, MD—April 25, 2023 – Cartesian Therapeutics, a fully integrated biopharmaceutical company pioneering RNA cell therapy for autoimmune diseases and cancer, today announced the appointment of three world-renowned scientists and engineers as charter members of the company’s Scientific Advisory Board (SAB): Prof. Jennifer Elisseeff (Johns Hopkins University), Prof. Andrés García (Georgia Institute of Technology), and Prof. David …

Cartesian Therapeutics Announces Appointment of Three World-Renowned Scientists and Engineers as Charter Members of Company’s Scientific Advisory Board Read More »

Cartesian Therapeutics Expands Clinical Advisory Board with Five Internationally Recognized Experts in Autoimmunity

Gaithersburg, MD—March 28, 2023 – Cartesian Therapeutics, a fully integrated biopharmaceutical company pioneering RNA cell therapy for autoimmune diseases and cancer, today announced the appointment of five internationally recognized experts in autoimmune diseases.  Cartesian’s appointments include distinguished physicians and scientists as leaders in clinical trials and medicine. “Cartesian is proud to have these prestigious, multidisciplinary advisors …

Cartesian Therapeutics Expands Clinical Advisory Board with Five Internationally Recognized Experts in Autoimmunity Read More »

Cartesian Therapeutics Strengthens Research and Innovation Leadership with appointment of Professor Christopher M. Jewell as Chief Scientific Officer

Gaithersburg, MD—February 14, 2023 – Cartesian Therapeutics, a fully integrated biopharmaceutical company pioneering RNA cell therapy for autoimmune diseases and cancer, today announced the appointment of Christopher M. Jewell, PhD/MS as Chief Scientific Officer. Dr. Jewell’s predecessor, Michael Singer, MD, PhD, has been named Chairman of the Board and Chief Strategy Officer. Dr. Jewell is …

Cartesian Therapeutics Strengthens Research and Innovation Leadership with appointment of Professor Christopher M. Jewell as Chief Scientific Officer Read More »

Cartesian Therapeutics Announces Dosing of First Participant in a Phase 2b Randomized Clinical Trial for Generalized Myasthenia Gravis

⦁ First placebo-controlled study of an engineered cell therapy Gaithersburg, MD, January 31, 2023 – Cartesian Therapeutics, a fully integrated, clinical-stage biotechnology company pioneering RNA cell therapies for autoimmune diseases and cancer, has dosed the first participant in its Phase 2b randomized controlled trial (RCT) for generalized myasthenia gravis (MG), an autoimmune disorder that causes …

Cartesian Therapeutics Announces Dosing of First Participant in a Phase 2b Randomized Clinical Trial for Generalized Myasthenia Gravis Read More »

Cartesian Therapeutics to Present Late-Breaking Data from Phase 1/2a Trial of RNA CAR T-cell Therapy in Patients with Generalized Myasthenia Gravis

– Data Presentation Today at 14th Myasthenia Gravis Foundation of America International Conference on Myasthenia and Related Disorders in Miami – GAITHERSBURG, Md., May 10, 2022  – Cartesian Therapeutics, a fully integrated clinical-stage biotechnology company pioneering RNA cell therapy in and beyond oncology, will present late-breaking interim data from its Phase 1/2a clinical trial of Descartes-08 in patients …

Cartesian Therapeutics to Present Late-Breaking Data from Phase 1/2a Trial of RNA CAR T-cell Therapy in Patients with Generalized Myasthenia Gravis Read More »

Cartesian Therapeutics Doses Patient with First Allogeneic RNA Cell Therapy for Multiple Myeloma

Descartes-25 engineered to deliver a combination of synergistically active anti-myeloma therapies directly to tumor microenvironment Product generated from Company’s Part 1271-compliant Master Cell Bank of human umbilical cord Mesenchymal Stem Cells Fifth IND in the five years since Cartesian was founded Gaithersburg, Md., January 25, 2022 – Cartesian Therapeutics, a fully integrated clinical-stage biotechnology company …

Cartesian Therapeutics Doses Patient with First Allogeneic RNA Cell Therapy for Multiple Myeloma Read More »

Scroll to Top